Cristina Popa
LightNews LightNews
nephroseeker.medsky.social
Cristina Popa
@nephroseeker.medsky.social
3K followers 1.1K following 2.1K posts
🩺 Nephrologist = kidney philosopher
📜History lover
🕊️ Aspiring to be better. Freethinker
📍 #NephJC editor-in-chief
📍@KIreportsbsky.social
📍ERAkidney #ERA25 social media co-leader
#NephSky #MedSky
Posts Replies Media Videos
Reposted by Cristina Popa
ajkd.bsky.social
In the Literature by Georgina Gyarmati:

Are Mother Glomeruli in Good or Bad Company?

bit.ly/4tchcUN (FREE)
February 1, 2026 at 11:00 PM
Reposted by Cristina Popa
hswapnil.medsky.social
telegram-based paper mill

retractionwatch.com/2026/01/26/s... on @retractionwatch.com

$165 for first author,
$110 for second author,
and $55 for the remaining slots

welcome to academic publishing!
Study is stolen, sold, published. Now the victim is accused of plagiarism
The year 2026 did not start off kindly for Vijayalakshmi S, an economics researcher at RV University in Bengaluru, India. She received a rejection letter from a journal noting that a paper of hers …
retractionwatch.com
February 1, 2026 at 5:01 PM
Reposted by Cristina Popa
hswapnil.medsky.social
super interesting mechanistic study

effect of potassium supplement on natriuresis, with and without lisinopril
in patients with and without CKD

academic.oup.com/ndt/article-...
VA
January 30, 2026 at 10:33 PM
Reposted by Cristina Popa
hswapnil.medsky.social
We are on Insta too

www.nephjc.com/news/nephjc-...
nephjc on insta
January 31, 2026 at 11:00 PM
Reposted by Cristina Popa
hswapnil.medsky.social
#TopNephrology stories of 2025

the podcast is out: www.nephjc.com/freelyfilter...

with @kidneyboy.bsky.social @captainchloride.bsky.social @medpeedskidneys.bsky.social @annagaddy.bsky.social @vipvargh.bsky.social @brianrifkin.bsky.social & @nephroseeker.medsky.social
FF 89 Top Stories of 2025 — NephJC
I know 2026 feels like it ihas been here for months, but only a few weeks ago we were celebrating the nephrology accomplishments of 2025. The New Filtrate came together to review the year.
www.nephjc.com
January 31, 2026 at 7:08 PM
Reposted by Cristina Popa
nephjc.bsky.social
To say it took a while is an understatement, because #NephJC has been around for 11 years (and still counting)...

🥁 We opened an Instagram account, so if you're around, can follow and interact 👣💞

#NephSky #Medsky
January 31, 2026 at 4:58 PM
Reposted by Cristina Popa
nephjc.bsky.social

Check the insightful #NephJC summary by Shellie Fravel, PharmD and Clemens Weber
POTCAST- K+ Pop and Arrhythmia Drop — NephJC
This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.
www.nephjc.com
January 28, 2026 at 2:05 AM
Reposted by Cristina Popa
nephjc.bsky.social
T2g

Secondary outcomes (Appropriate ICD therapy/VT)
👉15.3% high-normal K
👉 20.3% standard care
🎯HR 0.75 (95% CI 0.57–0.98)

a clear reduction in dangerous arrhythmias #NephJC

January 28, 2026 at 2:35 AM
Reposted by Cristina Popa
nephjc.bsky.social
Oh, the weather outside is frightful 🥶🥶
But #NephJC is so delightful,
and since you've no place to go #NephSky...
Come discuss POTCAST: potassium goals and cardiac arrhythmias 1/27/26 at 9pm EST on #Bluesky
Summary by @shelliefravel.bsky.social @salinesolut.bsky.social
www.nephjc.com/news/potcast
POTCAST- K+ Pop and Arrhythmia Drop — NephJC
This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.
www.nephjc.com
January 26, 2026 at 9:47 PM
Reposted by Cristina Popa
hswapnil.medsky.social
5 reasons to publish with KICR

www.theisn.org/blog/2026/01...

@theisn.org @arvindcanchi.bsky.social

#NephSky
Five compelling reasons to submit to Kidney International Case Reports™   - International Society of Nephrology
www.theisn.org
January 27, 2026 at 12:05 PM
Reposted by Cristina Popa
nephjc.bsky.social
¿Elevar el K⁺ al rango alto-normal puede reducir las descargas del DAI y las hospitalizaciones?

🎨Resumen visual por @jeyakumarmeyyappan.bsky.social
✍️Traducido por @dramiliflores.bsky.social

www.nephjc.com/news/2026/1/...
January 26, 2026 at 9:13 AM
Reposted by Cristina Popa
nephjc.bsky.social
🍌🥑Can pushing K⁺ to the high-normal range reduce ICD shocks and hospitalizations?

🎨 #Visualabstract by @jeyakumarmeyyappan.bsky.social

⏰ #NephJC chat on Jan 27, 9 pm EST

www.nephjc.com/news/2026/1/...
January 26, 2026 at 9:05 AM
Reposted by Cristina Popa
benoitbrilland.bsky.social
Our large kidney transcriptomic dataset of #ANCA #glomerulonephritis is now publicly available (www.ncbi.nlm.nih.gov/geo/query/ac...). Used to describe a strong renal interferon signature and a prognosis signature outperforming current classifications (links below). I hope it will be useful! 🚀
January 22, 2026 at 7:54 AM
Reposted by Cristina Popa
nephjc.bsky.social
1/10 Last #NephJC we discussed Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN #TenPostNephJC
Given the central role of complement dysregulation in C3 glomerulonephritis, we assessed whether complement-targeted therapies confer therapeutic benefit.
www.nejm.org/doi/full/10....
January 16, 2026 at 9:16 PM
Reposted by Cristina Popa
nephjc.bsky.social
9’/10
We wouldn’t have a complete view on C3GN treatment if we didn’t discuss iptacopan and the APPEAR C3G trial
Read the #NephJCshort by @nephroseeker.medsky.social and @drpallaviprasad.bsky.social
www.nephjc.com/news/2026/1/...
A ray of hope APPEARS for C3G — NephJC
The NephJC shorts on APPEAR-G3C randomized controlled trial: iptacopan in C3GN
www.nephjc.com
January 16, 2026 at 9:16 PM
Reposted by Cristina Popa
nephjc.bsky.social
10/10 ➡️Next up: 1/27/26, 9pm EST #NephJC POTCAST trial!
www.nejm.org/doi/abs/10.1...

👋thread by @thekidneywhisperer.bsky.social
Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias | NEJM
Hypokalemia and even low-normal plasma potassium levels increase the risk of ventricular arrhythmias among patients with cardiovascular disease. An assessment of a strategy of actively increasing p...
www.nejm.org
January 16, 2026 at 9:16 PM
nephroseeker.medsky.social
#ISNWCN social media team kickoff meeting was all about anticipation and good vibes ✨
theisn.org ISNkidneycare @theisn.org · 20d
📣 WCN’26 Social Media Team Kickoff Meeting
We’re delighted to welcome our new team members 🙌🏼
Meet the people behind the content:
🔗 theisn.org/wcn/media/so...
#ISNWCN
January 16, 2026 at 3:02 PM
Reposted by Cristina Popa
kireports.bsky.social
4/ Our #Skeetorial is based on a recent publication by Dr. Dana Kim and VA by @husamjz.bsky.social:
Sex Differences Across Corticosteroid Response and Outcomes in IgA Nephropathy
🔗https://www.sciencedirect.com/science/article/pii/S2468024925004851
January 15, 2026 at 8:13 PM
Reposted by Cristina Popa
nephjc.bsky.social
T0b
The pathophysiology of C3GN & IC-MPGN is thought to be caused by:
Genetic mutations or
Acquired defect of complement proteins or
Auto-antibodies against complement factors and/or regulating proteins. #NephJC

January 14, 2026 at 2:08 AM
nephroseeker.medsky.social
#NephJC
nephjc.bsky.social Nephrology Journal Club @nephjc.bsky.social · 23d
T0c
The new classification of MPGN relies on immunofluorescence (IF) patterns as well as pathobiology. #NephJC
January 14, 2026 at 2:14 AM
nephroseeker.medsky.social
Cristina Popa, Romanian nephrologist, no COI #NephJC
Super sleepy, 4 am 👉 lurking
Started gathering all the Christmas decorations, with these guys 😀
January 14, 2026 at 2:02 AM
Reposted by Cristina Popa
nephjc.bsky.social
✨It's that time of the year again, to nominate the most deserving people in our community for #NephJCKidneys award

👇Here's a reminder of previous winners #Nephsky

📌You can nominate worthy individuals/ initiatives by using the hashtag or by using the form

www.nephjc.com/news/2026/1/...
January 8, 2026 at 4:04 PM
Reposted by Cristina Popa
nephjc.bsky.social
Check out the VA for VALIANT from @nephromommy-akshu.bsky.social
#NephJC
www.nephjc.com/news/2026/1/11/valiant-the-visual-abstract
VALIANT: The Visual Abstract — NephJC
The VALIANT phase 3 RCT shows that proximal C3 inhibition with pegcetacoplan leads to a significantly greater reduction in proteinuria compared with placebo in patients with C3G and primary immune-com...
www.nephjc.com
January 12, 2026 at 12:53 PM
Reposted by Cristina Popa
nephjc.bsky.social
Wilst thou join us here, where the Sky is Blue? #NephJC
On 1/13/26 at 9pm EST 'tis true
We shall converse of the great knight's quest,
a VALIANT effort from Sir Pegcetacoplan vs complement! ⚔️
www.nephjc.com/news/valiant-c3g
A VALIANT effort to combat complement disorders with pegcetacoplan — NephJC
This week, we will discuss the VALIANT study, pegcetacoplan in C3G and IC MPGN.
www.nephjc.com
January 12, 2026 at 12:50 PM
Reposted by Cristina Popa
dramiliflores.bsky.social
🧬 C3G
APPEAR-C3G or VALIANT?

📉 Proteinuria vs placebo:
🔹 Iptacopan: 35%
🔹 Pegcetacoplan: 67%

🎯 Blocking factor B 🆚 🚫C3
Where would you place your bet today? #nephsky #Medsky @thelancet.com @nejm.org

🦋 join us today on #nephjc
January 13, 2026 at 3:34 PM